CANDEL THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
CANDEL THERAPEUTICS, INC. (CADL) reported Increase (Decrease) in Accounts Payable of $4.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.38M, a 136.98% increase year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.70M, a 234.91% increase year-over-year.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $33.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$744.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was $802.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$185.00K, a 511.11% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $45.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$1.21M, a 281.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.08M 10-Q · filed 2026-08-13 | $4.12M derived: sum of 3 quarters · filed 2026-08-13 | $3.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-14 | $1.73M derived: sum of 2 quarters · filed 2026-05-14 | $987.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$711.00K derived: sum of 2 quarters · filed 2026-03-12 | $295.00K derived: sum of 3 quarters · filed 2026-08-13 | $802.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$744.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $262.00K derived: sum of 2 quarters · filed 2026-08-13 | $769.00K 10-Q · filed 2025-11-13 | $713.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.51M 10-Q · filed 2026-08-13 | $1.46M derived: sum of 3 quarters · filed 2026-08-13 | $1.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $507.00K 10-Q · filed 2026-05-14 | $451.00K derived: sum of 2 quarters · filed 2026-05-14 | $311.00K derived: sum of 3 quarters · filed 2026-05-14 | $272.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$196.00K derived: sum of 2 quarters · filed 2026-03-12 | -$235.00K derived: sum of 3 quarters · filed 2026-03-12 | -$185.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$179.00K derived: sum of 2 quarters · filed 2025-11-13 | -$129.00K 10-Q · filed 2025-11-13 | $43.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $11.00K 10-Q · filed 2025-08-14 | $183.00K derived: sum of 3 quarters · filed 2025-08-14 | -$31.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $50.00K 10-Q · filed 2025-05-13 | $222.00K derived: sum of 2 quarters · filed 2025-05-13 | $8.00K derived: sum of 3 quarters · filed 2025-05-13 | -$54.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$42.00K derived: sum of 2 quarters · filed 2025-03-13 | -$104.00K derived: sum of 3 quarters · filed 2025-03-13 | $45.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$276.00K derived: sum of 2 quarters · filed 2024-11-14 | -$127.00K 10-Q · filed 2024-11-14 | -$671.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $87.00K 10-Q · filed 2024-08-13 | -$457.00K derived: sum of 3 quarters · filed 2024-08-13 | -$965.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $149.00K 10-Q · filed 2024-05-14 | -$395.00K derived: sum of 2 quarters · filed 2024-05-14 | -$903.00K derived: sum of 3 quarters · filed 2024-05-14 | -$485.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$1.05M derived: sum of 2 quarters · filed 2024-03-28 | -$634.00K derived: sum of 3 quarters · filed 2024-03-28 | -$1.21M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$90.00K derived: sum of 2 quarters · filed 2023-11-09 | -$669.00K 10-Q · filed 2023-11-09 | -$4.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$161.00K 10-Q · filed 2023-08-10 | $504.00K derived: sum of 3 quarters · filed 2023-08-10 | $685.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$579.00K 10-Q · filed 2023-05-11 | $86.00K derived: sum of 2 quarters · filed 2023-05-11 | $267.00K derived: sum of 3 quarters · filed 2023-05-11 | -$83.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $846.00K derived: sum of 2 quarters · filed 2023-03-30 | $496.00K derived: sum of 3 quarters · filed 2023-03-30 | $669.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $181.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$169.00K derived: sum of 2 quarters · filed 2022-11-10 | $4.00K 10-Q · filed 2022-11-10 | -$534.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$350.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$177.00K 10-Q · filed 2022-08-05 | -$715.00K derived: sum of 3 quarters · filed 2022-08-05 | $103.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $173.00K 10-Q · filed 2022-05-12 | -$365.00K derived: sum of 2 quarters · filed 2022-05-12 | $453.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $280.00K derived: sum of 2 quarters · filed 2022-03-29 | $289.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $818.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $827.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $9.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |